Seeking Alpha
08 Sept 2026, 13:53 UTC · 2d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Novartis experienced late-stage clinical failures for both pelacarsen and del-desiran. — Late-stage failures in the pipeline directly impair long-term growth projections and investor confidence in the R&D engine.
-0.80Rhapsido achieved phase 3 success in relapsing multiple sclerosis with a peak annual sales potential exceeding $3 billion. — A successful phase 3 trial for a potential blockbuster drug provides a significant new revenue stream and partially offsets other losses.
+0.60Novartis reiterated its 2025-2030 revenue growth guidance of 5-6% CAGR. — Maintaining guidance suggests management believes the pipeline successes balance the failures, providing a floor for valuation.
+0.20Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
The company suffered late-stage drug failures causing shares to plunge, though positive data for Rhapsido provides a partial offset.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
9h ago
